Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Moody's Corporation (MCO) Price & Performance

BioNano Genomics IncTrade
Moody's CorporationTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Moody's Corporation — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Moody's Corporation trades at $479.5 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 6041× BioNano Genomics Inc's market cap, and Moody's Corporation pays a 0.86% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.

BNGOMCO
Market Cap
$13.66M$82.52B
Sector
HealthFinancials
52-Week High
$4.92$539.61
52-Week Low
$1.06$412.23
Enterprise Value
$16.26M$88.54B
Dividend Yield
0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

Moody's Corporation

Moody's Corporation (MCO) trades at $477.00, down 0.24% on the day, with strong fundamentals including 80.15% ROE and 34.25% net margin. The stock shows bearish technical signals but maintains robust earnings momentum with three consecutive quarterly beats. Revenue growth accelerated to $7.72 billion in 2025, while analyst consensus remains bullish with a $561.88 price target representing 18% upside potential.

MCO presents a compelling growth story with premium valuation metrics (P/E 30.23) justified by consistent earnings outperformance and dominant market position. Key risks include sensitivity to debt issuance cycles and elevated valuation multiples. The combination of strong profitability, analyst support, and dividend payments supports a positive long-term outlook despite near-term technical weakness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.

Read more on MCO